2 active not recruiting, 1 completed, 1 withdrawn. 2 Early Phase 1, 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Active not recruiting 2 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow David Bushnell: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors [212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT - Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung | Early Phase 1 | Active not recruiting | David Bushnell | 24 | 2023-11-10 | 2025-11-04 |
| A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Lutathera, Azedra - Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors | Phase 1 / Phase 2 | Withdrawn | David Bushnell | 2022-09-30 | 2024-04-29 | |
| Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors 90Y-DOTA-3-Tyr-Octreotide, 131I-MIBG - Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting | Early Phase 1 | Active not recruiting | David Bushnell | 20 | 2017-05-07 | 2023-08-16 |
| Combination Targeted Radiotherapy in Neuroendocrine Tumors 131-I MIBG and 111-In pentetreotide, 131-I MIBG and In-111 DOTATATE - Neuroendocrine Tumors | Not applicable | Completed | David Bushnell | 2 | 2006-09-01 | 2016-07-21 |
Neuroendocrine Tumors (4) · Adenoma, Islet Cell (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Recurrence (1)
3-Iodobenzylguanidine (3) · 90Y-octreotide, DOTA-Tyr(3)- (1) · lutetium Lu 177 dotatate (1) · pentetreotide (1)
United States (4)
P50CA174521 (2), R01CA243014 (1)